Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Astellas_Pharma
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:focusesOn |
gene therapy
rare neuromuscular diseases |
| gptkbp:foundedIn |
2012
|
| gptkbp:founder |
gptkb:Matthew_Patterson
|
| gptkbp:headquartersLocation |
gptkb:San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Audentes Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:AT132
gptkb:AT307 gptkb:AT845 AT342 |
| gptkbp:parentCompany |
gptkb:Astellas_Pharma
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:BOLD
|
| gptkbp:website |
https://www.audentestx.com/
|
| gptkbp:bfsParent |
gptkb:Astellas_Pharma
|
| gptkbp:bfsLayer |
5
|